Gyre Therapeutics, Inc. Deferred Income Tax Expense (Benefit)
Gyre Therapeutics, Inc. (GYRE) reported Deferred Income Tax Expense (Benefit) of -$1.11 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:DeferredIncomeTaxExpenseBenefit · last filed 2026-03-13
- Gyre Therapeutics, Inc. deferred income tax expense (benefit) for fiscal 2025 was -$1.11M.
- Gyre Therapeutics, Inc. deferred income tax expense (benefit) for fiscal 2024 was -$1.00M.
- Gyre Therapeutics, Inc. deferred income tax expense (benefit) for fiscal 2023 was -$834.00K.
- Gyre Therapeutics, Inc. deferred income tax expense (benefit) for fiscal 2022 was -$890.00K.
| Period end | Deferred Income Tax Expense (Benefit) 12 month |
|---|---|
| 2025-12-31 | -$1.11M 10-K · filed 2026-03-13 |
| 2024-12-31 | -$1.00M 10-K · filed 2026-03-13 |
| 2023-12-31 | -$834.00K 10-K · filed 2025-03-17 |
| 2022-12-31 | -$890.00K 10-K · filed 2024-03-27 |
| 2014-12-31 | $72.00K 10-K · filed 2015-03-16 |
| 2013-12-31 | $7.00K 10-K · filed 2015-03-16 |
| 2012-12-31 | -$101.00K 10-K · filed 2015-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |